Omeros, which a biotech company focused on inflammation/pain and disorders of the central nervous system, announced terms for its IPO on Wednesday. The Seattle, WA-based company, which was founded in 1994, plans to raise $75 million by offering 6,820,000 at a...read more
Bioheart, a biotechnology company focused on using cells derived from a patient's body for treatment of heart damage, priced its 1.1 million share offering at $5.25 on Tuesday, the midpoint of the revised range. The company had originally filed for an offering...read more
In the latest of a series of revisions, BioHeart, a biotechnology company focused on using cells derived from a patient's body for treatment of heart damage, amended the terms for its IPO. The company now plans to offer 1.1 million shares at a range of $5.00-$5...read more
BioHeart, which focuses on using cells derived from a patient's body for treatment of heart damage, filed terms Thursday with the SEC for its upcoming iPO. The company plans to offer 3.6 million shares at a price range of $14 to $16 per share. BMO Capital...read more
Seattle-based biotech Omeros sets IPO terms
Omeros, which a biotech company focused on inflammation/pain and disorders of the central nervous system, announced terms for its IPO on Wednesday. The Seattle, WA-based company, which was founded in 1994, plans to raise $75 million by offering 6,820,000 at a...read more
Biotech company BioHeart prices at midpoint of revised range
Bioheart, a biotechnology company focused on using cells derived from a patient's body for treatment of heart damage, priced its 1.1 million share offering at $5.25 on Tuesday, the midpoint of the revised range. The company had originally filed for an offering...read more
Biotech company BioHeart amends IPO terms
In the latest of a series of revisions, BioHeart, a biotechnology company focused on using cells derived from a patient's body for treatment of heart damage, amended the terms for its IPO. The company now plans to offer 1.1 million shares at a range of $5.00-$5...read more
Biotech company BioHeart announces terms
BioHeart, which focuses on using cells derived from a patient's body for treatment of heart damage, filed terms Thursday with the SEC for its upcoming iPO. The company plans to offer 3.6 million shares at a price range of $14 to $16 per share. BMO Capital...read more